MDA-MB-231 Xenograft Model

MDA-MB-231 Xenograft Altogen Labs

MDA-MB-231 xenograft model

The MDA-MB-231 cell line (human breast) is used to create the CDX (Cell Line Derived Xenograft) MDA-MB-231 xenograft mouse model.  The MDA-MB-231 xenograft model is HER2 negative, CK18 and EGFR positive and exhibits tumor growth inhibition from herceptin, lapatinib and trastuzumab.

Basic study design

  1. Cells are continually grown under asceptic conditions prior to collection and in an exponential phase.
  2. Post- collection, cells viability is determined.  A 98% minimum viability via trypan blue exclusion assay is required.
  3. All cell suspension concentrations are adjusted by volume such that a 100 uL injection of the matrigel + MDA-MB-231 cell suspension contains one million cells.  The cell suspension is inoculated s.c. into a flank of one hind leg per.  NOD/SCID or athymic BALB/C are used and are 10-12 weeks old.
  4. Calipering of tumors determines start of the study, with an expectation of 50-150 mm3 tumors.  Sorting of animals into cohorts and administration of test compounds are performed according to the established treatment schedule.
  5. Daily tumor measurements are recorded.  The tumor size limit in the study plan determines the completion of the study.  Necropsies are performed for tumor removal, weights are recorded and then documented digitally.
  6. Tumors and tissues can be snap frozen in Liquid Nitrogen, stabilized in RNAlater or nucleic acids isolated.

Get Instant Quote for
MDA-MB-231 Xenograft Model

Xenograft animal models are used to assess the effectiveness of drugs against specific types of cancer. New medicines are tested on staged tumor growths that have been engrafted via subcutaneous or orthotopic inoculation in an immunocompromised mouse or rat model. All clinically approved anti-cancer agents have been evaluated with conventional preclinical in vivo models. Xenograft studies can be highly complex, starting with the selection of the appropriate animal model, choice of tumorigenic cell line, administration method, dosing, analysis of tumor growth rates and tumor analysis (histology, mRNA and protein expression levels).

Altogen Labs provides an array of laboratory services using over 30 standard Cell Line Derived Xenograft (CDX) models and over 20 PDX models. Researchers investigating the role of specific proteins or gene products in regulating tumor growth can benefit from development of protein overexpression (genetically engineered to ectopically express proteins, tumor suppressors, or oncogenes) and RNAi cell lines with long term gene silencing. Altogen Labs provides quantitative gene expression analysis of mRNA expression (RT-PCR) and protein expression analysis using the WES system (ProteinSimple).

The dosing of the experimental compound of interest is initiated, for a staged study, when the mean tumor size reaches a specified volume (typically 50-100 mm3). In an unstaged study, the dosing of the compound of interest is initiated immediately after xenografting. Mice are dosed once or twice a day for 28 days (or other desired study duration) via the chosen route of administration. Tumor volume (mm3) is calculated via the “(W x W x L) / 2” formula, where W is tumor width and L is tumor length.

Animal handling and maintenance at the Altogen Labs facility is IACUC-regulated and GLP-compliant. Following acclimation to the vivarium environment, mice are sorted according to body mass. The animals are examined daily for tumor appearance and clinical signs. We provide detailed experimental procedures, health reports and data (all-inclusive report is provided to the client that includes methods, results, discussion and raw data along with statistical analysis). Additional services available include collection of tissue, histology, isolation of total protein or RNA and analysis of gene expression. Our animal facilities have the flexibility to use specialized food or water systems for inducible gene expression systems.

Following options are available for the MDA-MB-231 xenograft model:

  • MDA-MB-231 Tumor Growth Delay (TGD; latency)
  • MDA-MB-231 Tumor Growth Inhibition (TGI)
  • Dosing frequency and duration of dose administration
  • Dosing route (intravenous, intratracheal, continuous infusion, intraperitoneal, intratumoral, oral gavage, topical, intramuscular, subcutaneous, intranasal, using cutting-edge micro-injection techniques and pump-controlled IV injection)
  • MDA-MB-231 tumor immunohistochemistry
  • Alternative cell engraftment sites (orthotopic transplantation, tail vein injection and left ventricular injection for metastasis studies, injection into the mammary fat pad, intraperitoneal injection)
  • Blood chemistry analysis
  • Toxicity and survival (optional: performing a broad health observation program)
  • Gross necropsies and histopathology
  • Positive control group employing cyclophosphamide, at a dosage of 50 mg/kg administered by intramuscular injection to the control group daily for the study duration
  • Lipid distribution and metabolic assays
  • Imaging studies: Fluorescence-based whole body imaging, MRI

Get Instant Quote for
MDA-MB-231 Xenograft Model